Corporate Banner
Satellite Banner
Technology Networks Header
Monday, November 24, 2014
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Proteomics for Systems Toxicology
MS-based proteomics is maturing into a robust technology for the measurement of proteome-wide exposure effects.
How A Mutant Gene Can Cause Deafness
Scientists at The Scripps Research Institute (TSRI) have discovered how one gene is essential to hearing, uncovering a cause of deafness and suggesting new avenues for therapies.
Developing a Noninvasive Test for Endometriosis
UCSF researchers identify patterns of genetic activity that could help in early detection of disorder.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Powerful Method To Speed Cancer Drug Discovery Unveiled
The new method lets researchers identify weak and previously undetectable interactions between proteins inside living cells.
Brain-dwelling Worm in UK Man's Head Sequenced
Tapeworm removed from UK resident's brain reveals genetic secrets of an elusive Far East parasite.
Researchers Tease Out Glitches in Immune System's Self-Recognition
A new study revises understanding of how the process works and sheds light on autoimmune disease.
Crowdsourcing Science To Beat Psa
Scientists are hoping that crowdsourcing knowledge from the international science community will help them find the answer to a lethal kiwifruit disease.
Breakthrough in Managing Yellow Fever Disease
UC Riverside-led research could lead to antiviral therapeutics and better diagnostics to prevent spread of potentially fatal viral infection.
Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1
Results presented at international conferences in Philadelphia and New Orleans.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv